PJP Invesco Pharmaceuticals ETF
- 80.851
- -0.285-0.35%
Johnson & Johnson-backed Rapport Therapeutics Files for $100M IPO
Medtronic Study of Affera Sphere-9 Catheter Meets Endpoints
Amgen Unusual Options Activity
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options h
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The return of Roaring Kitty, aka Keith Gill, on social media increased interest in meme stocks and may have kickstarted a short rally to start the trading week.While there are several ETFs that provid
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company.The analyst notes that the company has positioned itself to absorb Humira biosimilar erosion and achieve mod
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Moderna Vaccine Patent Upheld by European Patent Office: Report
'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The MRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 vaccine, in a boon for the mRNA-vaccine maker in its ongoing legal fight to recoup pandem
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve
Evaluating Eli Lilly and Co Against Peers In Pharmaceuticals Industry
In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehe
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK plc (NYSE:GSK) confirmed the sale of 385.3 million shares in Haleon plc (NYSE:HLN) for $1.58 billion. The shares represented around 4.2% of the issued share capital of Haleon.Following the settlem
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
Thursday, the FDA approved Amgen Inc's (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on o
Regeneron Wins Temporary Restraining Order Preventing Eylea Generics
There is also an atmosphere where they want to determine a slight increase in Dow futures = US stocks
Both Dow futures, S&P 500, and NASDAQ 100 are moving slightly higher in the US stock index futures market. In response to a series of economic indicators, starting with the US Consumer Price Index (CPI) this week, the market strengthened FRB interest rate cut observations, and in the short-term financial market, interest rate cuts are expected twice within the year in September and December.
The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
5 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent rati
Dividend Roundup: Home Depot, Alibaba, Johnson & Johnson, Yum! Brands, and More
AbbVie Says It Will Present New Data Supporting Leading Gastroenterology Portfolio At 2024 Digestive Disease Week; Company To Present 15 Abstracts, Including Three Oral Presentations, In Crohn's Disease And Ulcerative Colitis
The 2024 Digestive Disease Week (DDW) Annual Meeting will be held on May 18-21 in Washington, D.C., and virtually.Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYR
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 21.69% Cantor Fitzgerald → $200 Initiates Coverage On → Overweight 04/29/2024 13.78% Barclays $
Reported Earlier, FDA Approves Amgen's IMDELLTRA (Tarlatamab-dlle) The First And Only T-Cell Engager Therapy For The Treatment Of Extensive-Stage Small Cell Lung Cancer
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid TumorIMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Su
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:PFE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this